Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Contact information



Primary contact

Ms Joanne Meerabux


Contact details

Centre for Experimental Cancer Medicine
Institute of Cancer
Barts and The London School of Medicine and Dentistry
Lower Ground Floor Old Anatomy Building
Charterhouse Square
United Kingdom

Additional identifiers

EudraCT number

2008-002286-32 number


Protocol/serial number


Study information

Scientific title

Phase I/II study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) or both monoclonal antibodies with intensive chemotherapy in adults with recurrent B-precursor acute lymphoblastic leukaemia (ALL)



Study hypothesis

This is a phase I/II study to determine the safety and tolerability of the combination of veltuzumab and epratzumab with intensive chemotherapy in patients with relapsed B-cell acute lymphoblastic leukaemia (ALL). A maximum of 55 patients will be treated with a combination of UKALL XII induction chemotherapy and the monoclonal antibodies veltuzumab and epratuzumab. Veltuzumab and epratuzumab are humanised monoclonal antibodies that target CD20 and CD22 surface proteins, respectively. Both of these proteins are expressed on ALL tumour B cells.

One group of patients will receive UKALL XII + veltuzumab; a second, UKALL XII + epratuzumab and if limited toxicity is found in these first two groups, a third group will receive, UKALL XII + both veltuzumab and epratuzumab. Patients will be assessed for safety, tolerability and disease response. Safety and tolerability will be measured by the number of dose limiting toxicities (DLTs) in each group. Disease response will be measured by the microscopic appearance of patient bone marrow samples at day 29, and by molecular tests for tumour cells in bone marrow.

Ethics approval

North London REC 3 approved on the 10th August 2009 (ref: 09/H0709/42)

Study design

Multicentre non-randomised interventional screening and treatment trial

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting

GP practices

Trial type


Patient information sheet

Not available in web format, please contact to request a patient information sheet


Topic: National Cancer Research Network; Subtopic: Haematological Oncology; Disease: Leukaemia (acute lymphoblastic)


Cohort A patients:
1. UKALL 12 chemotherapy
2. Veltuzumab at 200 mg/m^2 intravenously on days 8 (as a 2-hour infusion), 15, 22 and 29 (as a 1-hour infusion)

Cohort B patients:
1. UKALL 12 chemotherapy
2. Epratuzumab at 360 mg/m^2 intravenously on days 8, 15, 22, 29 (as a 1-hour infusion)

Cohort C patients:
1. UKALL 12 chemotherapy
2. Epratuzumab and veltuzumab at 360 mg/m^2 and 200 mg/m^2 respectively, intravenously on days 8, 15, 22, 29.

All patients will receive UKALL 12 chemotherapy as shown below:
1. Daunorubicin given at 60 mg/m^2 intravenously on days 1, 8, 15 and 22
2. Dexamethasone given at 10 mg/m^2 orally on days 1 - 5 and days 11 - 14
3. L-asparaginase given at 5,000 iU/m^2 intravenously or intramuscularly on days 17, 19, 21, 23, 25, 27 and 29
4. Methotrexate 12.5 mg given intrathecally on day 24 only (unless central nervous system [CNS] leukaemia detected at relapse)
5. Vincristine given at 1.4 mg/m^2 intravenously on days 1, 8, 15 and 22

Follow-up length: 1 months
Study entry: registration only

Intervention type



Phase I/II

Drug names

Veltuzumab, epratzumab

Primary outcome measure

Assess the safety and tolerability of the combination of veltuzumab and/or epratuzumab with intensive chemotherapy for recurrent adult B-precursor ALL by scoring dose limiting toxicity events in patients.

Secondary outcome measures

Achievement of morphological and molecular complete remission on Day 29 bone marrow

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Aged between 16 and 65 years, either sex
2. Confirmed diagnosis of first recurrence of B-precursor ALL (according to the World Health Organization [WHO] classification)
3. First complete remission (CR1) greater than 6 months
4. WHO/Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 and well enough to receive intensive combination chemotherapy
5. Negative pregnancy test in women of childbearing potential. Women will not be considered of child bearing potential if they have undergone surgical removal of the uterus or are post menopausal and have been amenorrhoic for at least 24 months.
6. Patients must have a cardiac ejection fraction of greater than 50%
7. Patients must have adequate organ function:
7.1. Renal function – serum creatinine less than 2.5 x upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) greater than 50 ml/min (measured EDTA or estimated creatinine clearance, e.g., Cockcroft & Gault)
7.2. Liver function - bilirubin/alanine aminotransferase (ALT) less than 2.5 x ULN
8. Patients must be able to comply with the study schedule

Participant type


Age group




Target number of participants

Planned sample size: 55; UK sample size: 55

Total final enrolment


Participant exclusion criteria

1. Patients with Philadelphia positive (Ph +ve) ALL
2. Patients at 2nd or greater relapse of their ALL
3. Patients should not have received chemotherapy for relapsed ALL (except corticosteroids for a maximum of 5 days, before joining the study)
4. Patients who have already received greater than 340 mg/m^2 daunorubicin (or equivalent total anthracycline dose) therapy
5. Patients who have received prior mediastinal radiotherapy
6. Patients with co-morbidities: e.g. uncontrolled hypertension and or poorly controlled diabetes which in the PI's opinion makes them unsuitable for the study
7. Patients with severe psychiatric disorders which in the PI's opinion makes them unsuitable for trial participation
8. Females of childbearing potential and all males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study and for up to 3 months after the last dose of study medication. Note: Subjects are not considered of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are post-menopausal (that is amenorrheic for 24 months).
9. Females of childbearing potential must have a negative pregnancy test within 7 days prior to starting the study
10. Females must not be breastfeeding
11. Patients may not receive any other investigational agent during the study
12. Patients should not have received any antibody therapy within 9 months of joining this study

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Centre for Experimental Cancer Medicine
United Kingdom

Sponsor information


Queen Mary University of London

Sponsor details

Mile End Road
E1 4NS
United Kingdom

Sponsor type




Funder type


Funder name

Cancer Research UK (CRUK) (UK) (ref: C1574/A9768)

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Funder name

Immunomedics Inc (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Available at:

Publication list

Publication citations

Additional files

Editorial Notes

20/05/2019: The total final enrolment was added. 08/03/2019: A link was added to the basic results (scientific) field. 26/03/2018: No publications found, verifying study status with principal investigator. 10/02/2015: No publications found, verifying study status with principal investigator.